Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda
Milan's largest public hospital, whose cancer centre under Salvatore Siena and Andrea Sartore-Bianchi ran HERACLES, the trial that proved HER2 is a target in bowel cancer.
Overview
The Niguarda Cancer Center is the oncology department of Milan's Niguarda hospital, a large public teaching hospital of the University of Milan. Under Salvatore Siena it built a programme in molecular oncology of colorectal cancer, running HERACLES, the first trial to show that HER2-directed therapy works in HER2-amplified colorectal cancer, contributing to the panitumumab trials that established RAS testing, and hosting the phase 1 unit that led DESTINY-CRC01. Andrea Sartore-Bianchi directs its clinical research and precision oncology programme.
- Colorectal cancer molecular oncology
- Phase 1 trials
- Precision oncology
Milan oncologist who was lead author of HERACLES, the first trial to show that HER2-targeted drugs work in HER2-amplified colorectal cancer.
Milan oncologist who co-led HERACLES and was lead author of DESTINY-CRC01, which showed trastuzumab deruxtecan is active in HER2-positive colorectal cancer, and a leader of the anti-EGFR antibody trials in the disease.